Document is current
Any future updates will be listed below
-
Authors
Eerkens, Anneke L. https://orcid.org/0000-0001-8823-196X
Brummel, Koen https://orcid.org/0000-0003-1983-450X
Vledder, Annegé
Paijens, Sterre T.
Requesens, Marta https://orcid.org/0000-0001-5559-8845
Loiero, Dominik https://orcid.org/0000-0002-0452-0068
van Rooij, Nienke
Plat, Annechien
Haan, Floris-Jan
Klok, Patty
Yigit, Refika https://orcid.org/0000-0001-7379-2203
Roelofsen, Thijs
de Lange, Natascha M.
Klomp, Rie https://orcid.org/0000-0003-3312-0511
Church, David https://orcid.org/0000-0002-4617-962X
ter Elst, Arja
Wardenaar, René https://orcid.org/0000-0001-9891-1897
Spierings, Diana https://orcid.org/0000-0001-8403-474X
Foijer, Floris https://orcid.org/0000-0003-0989-3127
Koelzer, Viktor Hendrik https://orcid.org/0000-0001-9206-4885
Bosse, Tjalling https://orcid.org/0000-0002-6881-8437
Bart, Joost https://orcid.org/0000-0002-0985-071X
Jalving, Mathilde https://orcid.org/0000-0002-9142-9050
Reyners, Anna K. L. https://orcid.org/0000-0003-1678-7816
de Bruyn, Marco https://orcid.org/0000-0001-9819-9131
Nijman, Hans W. https://orcid.org/0000-0002-1821-3042
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (13537)
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 26 August 2024
First Online: 3 September 2024
Competing interests
: HWN and MB received grants from the Dutch Cancer Society (KWF), the European Research Council (ERC), Health Holland (HH), Mendus, BioNovion, Aduro Biotech, Vicinivax, Genmab and IMMIOS (all paid to the institute); received non-financial support from BioNTech, Surflay Nanotec and Merck Sharp & Dohme; are stock option holders in Sairopa. DC reports to be part of the advisory board for Merck Sharp & Dohme, his immediate family member is an Amgen employee, and received funding from HalioDx, unrelated to the subject of this manuscript. VHK served as an invited speaker on behalf of Sharing Progress in Cancer Care (SPCC) and Indica Lab, reports to be part of the advisory board of Takeda, and has sponsored research agreements with Roche and IAG, all unrelated to the current trial. TB received grants from the Dutch Cancer Society, unrelated to the subject of this manuscript. JB received grants from the Dutch Cancer society and AstraZeneca. MJ reports to be part of the advisory board of Pierre Fabre, AstraZeneca, BMS, and GSK. All other authors declare no competing interests.
